Conference call/webinar on bipolar androgen therapy (BAT)

For those who are interested, the Answer Cancer Foundation has let us know that they will be holding an educational conference call/webinar at 8:00 pm Eastern (5:00 pm Pacific) today on the subject of bipolar androgen therapy in the treatment of advanced prostate cancer. … READ MORE …

SpaceOAR hydrogel — is the difference worthwhile?

SpaceOAR hydrogel is spacer injected between the rectum and the prostate that increases their separation (in men being treated with external beam radiation therapy). This allows less radiation targeted at the prostate to hit the rectum. The research group published an interim 15-month report in 2015, and now Hamstra et al. have published their final report based on 3 years of follow-up. … READ MORE …

Tookad-Soluble + VTP effective and safe in treatment of low-risk prostate cancer

Another new media report (based on data just published in Lancet Oncology) states that “vascular-targeted photodynamic therapy” or VTP in combination with an experimental drug called padeliporfin or WST11 can be used to successfully treat low-risk prostate cancer. … READ MORE …

Dose escalation for salvage radiation therapy

In the late 1990s and early 2000s, the advent of more accurate linear accelerators (LINACs) and image-guidance technology for delivering therapeutic X-rays to the prostate in the treatment of prostate cancer changed the dose that could be safely given. … READ MORE …

ADT and risk for diagnosis with dementia? “Not in the UK”, they say!

Just a few weeks ago we reported data from a study in California suggesting an association between treatment with androgen deprivation therapy (ADT) for prostate cancer and subsequent risk for diagnosis with dementia or Alzheimer’s disease. … READ MORE …

Focal laser ablation — a CureTalk discussion

At 6:00 p.m. this evening, Eastern Time, here in the USA, we will be collaborating with our friends at CureTalks to provide an introduction to focal laser ablation in the treatment of prostate cancer. To sign up, to listen in, or ask questions, please click here. … READ MORE …

5-Year SBRT trial: high cancer control, low toxicity

Data from a 5-year-long, multi-institutional trial, reported at the recent ASTRO meeting, showed that stereotactic body radiation therapy (SBRT) had high rates of cancer control and low toxicity. … READ MORE …